Sandler Alan B.
Chief Development Officer
Sandler Alan B. has filed 2 SEC Form 4 filings (8 transaction rows) across 1 company, with disclosures dating back to 2026. 2 of those filings fall inside the rolling window. Most recent filing: Oct 1, 2026.
On the most recent filing, Sandler Alan B. is listed as Chief Development Officer at Revolution Medicines, Inc. Inside the rolling window, Sandler Alan B. reported no open-market purchases and 2 open-market sales totaling $1.3M in RVMD. The largest disclosed transaction in the window is a sale of 6,309 RVMD shares on Sep 29, 2026, worth $1.3M.
Companies traded
Other insiders at RVMD
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$1.3M
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Sandler Alan B. made?
Sandler Alan B. has filed 2 SEC Form 4 filings (8 transaction rows) across 1 company since 2026.
Which companies does Sandler Alan B. trade?
Sandler Alan B. has filed SEC Form 4 disclosures for 1 company, including RVMD.
When was Sandler Alan B.'s most recent SEC Form 4 filing?
Sandler Alan B.'s most recent SEC Form 4 filing on Tracefour is dated Oct 1, 2026.
What is Sandler Alan B.'s job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Sandler Alan B. is listed as Chief Development Officer.
What is Sandler Alan B.'s total buy and sell value in the current window?
Inside the rolling retention window, Sandler Alan B. bought $0 and sold $1.3M based on SEC Form 4 filings.
What was Sandler Alan B.'s largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 6,309 RVMD shares on 2026-09-29, worth $1.3M, per SEC Form 4 filings.